Compare AQST & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AQST | MRVI |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 504.0M | 472.8M |
| IPO Year | 2007 | 2020 |
| Metric | AQST | MRVI |
|---|---|---|
| Price | $4.19 | $3.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $9.00 | $4.13 |
| AVG Volume (30 Days) | 1.0M | ★ 1.8M |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ N/A | N/A |
| Revenue | $67,430,000.00 | ★ $185,743,000.00 |
| Revenue This Year | $10.08 | $12.54 |
| Revenue Next Year | $49.60 | $7.87 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.77 | N/A |
| 52 Week Low | $2.22 | $1.96 |
| 52 Week High | $7.55 | $4.11 |
| Indicator | AQST | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 53.36 | 62.41 |
| Support Level | $3.70 | $3.65 |
| Resistance Level | $4.35 | $3.83 |
| Average True Range (ATR) | 0.15 | 0.22 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 44.44 | 91.50 |
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.